Duke doctor named new chair of NCCN board of directors

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 19 No 4
Volume 19
Issue 4

Thomas A. D’Amico, MD, has been elected chair of the board of directors of the National Comprehensive Cancer Network.

Thomas A. D'Amico, MD, has been elected chair of the board of directors of the National Comprehensive Cancer Network.

Dr. D'Amico is director of clinical oncology, program director of thoracic surgery, and professor in the department of surgery at Duke Comprehensive Cancer Center at Duke University in Durham, N.C.

His areas of expertise include the molecular biology of lung cancer, esophageal cancer, and also thoracic surgery. He is a member of several NCCN committees, and serves on the NCCN guidelines panel for esophageal/gastric cancers as well as on the panel for non-small-cell lung cancer.

Dr. D'Amico was previously vice-chair of the NCCN board and succeeds Al B. Benson III, MD, as chair.

Recent Videos
Thomas Powles, MBBS, MRCP, MD, highlighted fatigue, nausea, and peripheral neuropathy as toxicities observed with enfortumab vedotin plus pembrolizumab.
According to Megan Mullins, PhD, MPH, challenging cultural norms surrounding death and dying may reduce the receipt of low-value end-of-life cancer care.
Earlier and more frequent talks about disabling ICDs with patients receiving end-of-life care and their families may help avoid excessive pain.
3 experts in this video
3 experts in this video
Large international meetings may facilitate conversations regarding disparities of care outside of high-income countries.
6 experts are featured in this series.
6 experts are featured in this series.
Related Content